Prevention and early detection of prostate cancer

The Lancet Oncology

Volumn 15, Issue 11, 2014, Pages e484-e492

  Cuzick, Jack ^a   Thorat, Mangesh A ^a   Andriole, Gerald ^b   Brawley, Otis W ^c,d   Brown, Powel H ^e   Culig, Zoran ^f   Eeles, Rosalind A ^g,h   Ford, Leslie G ⁱ   Hamdy, Freddie C ^j   Holmberg, Lars ^l,m   Ilic, Dragan ⁿ   Key, Timothy J ^k   Vecchia, Carlo La ^o   Lilja, Hans ^k,p,q   Marberger, Michael ^r   Meyskens, Frank L ^s   Minasian, Lori M ⁱ   Parker, Chris ^h   Parnes, Howard L ⁱ   Perner, Sven ^t   Rittenhouse, Harry ^u   Schalken, Jack ^v   Schmid, Hans Peter ^w   Schmitz Dräger, Bernd J ^x   Schröder, Fritz H ^y   Stenzl, Arnulf ^z   Tombal, Bertrand ^aa   Wilt, Timothy J ^ab   Wolk, Alicja ^ac   more..

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARNES JEWISH HOSPITAL   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l KING'S COLLEGE LONDON   (United Kingdom)

^m UPPSALA UNIVERSITY   (Sweden)

ⁿ MONASH UNIVERSITY   (Australia)

^o UNIVERSITY OF MILAN   (Italy)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q LUND UNIVERSITY   (Sweden)

^r MEDICAL UNIVERSITY OF VIENNA   (Austria)

^s UNIVERSITY OF CALIFORNIA   (United States)

^t UNIVERSITY HOSPITAL BONN   (Germany)

^u Director of Assay Development IR2Dx Inc Moraga   (United States)

^v RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^w Kantonsspital St Gallen Klinik fur Urologie   (Switzerland)

^x Urologie 24 Urologie Schön Klinik Nürnberg Fürth   (Germany)

^y ERASMUS MEDICAL CENTER   (Netherlands)

^z UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^aa UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^ab UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^ac KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLIN D1; DUTASTERIDE; EFLORNITHINE; FINASTERIDE; KALLIKREIN; LYCOPENE; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; SMAD4 PROTEIN; SOMATOMEDIN C; STEROID 5ALPHA REDUCTASE INHIBITOR; SULFORAPHANE; TUMOR MARKER;

ANTIGEN DETECTION; BODY WEIGHT; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CELL CYCLE PROGRESSION; DIET; EARLY DIAGNOSIS; FAMILY HISTORY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC ASSOCIATION; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LIFESTYLE MODIFICATION; ONCOGENE; OVERALL SURVIVAL; PHYSICAL ACTIVITY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SMOKING CESSATION; SURVIVAL RATE; AGE; AGED; BLOOD; EVIDENCE BASED MEDICINE; LIFESTYLE; MALE; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PRIMARY PREVENTION; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTOR; RISK REDUCTION; TUMOR INVASION; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BIOPSY, NEEDLE; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOHISTOCHEMISTRY; LIFE STYLE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PRIMARY PREVENTION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84908118271     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70211-6     Document Type: Review

References (85)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer; 127: 2893-917.
2. Lane JA, Donovan JL, Davis M, et al. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014, published online Aug 19. http://dx.doi.org/10.1016/S1470-2045(14)70361-4.
3. Armitage P, Doll R The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 1954, 8:1-12.
4. Armitage P, Doll R A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer 1957, 11:161-169.
5. Merrill RM, Sloan A Risk-adjusted incidence rates for prostate cancer in the United States. Prostate 2012, 72:181-185.
6. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61:1079-1092.
7. Goggins WB, Wong G Cancer among Asian Indians/Pakistanis living in the United States: low incidence and generally above average survival. Cancer Causes Control 2009, 20:635-643.
8. Hemminki K, Ankerst DP, Sundquist J, Mousavi SM Prostate cancer incidence and survival in immigrants to Sweden. World J Urol 2013, 31:1483-1488.
9. Kiciński M, Vangronsveld J, Nawrot TS An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis. PLoS One 2011, 6:e27130.
10. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
11. Eeles RA, Olama AA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013, 45:385-391. 391e1-2.
12. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013, 31:1748-1757.
13. Goh CL, Eeles RA Germline genetic variants associated with prostate cancer and potential relevance to clinical practice. Recent Results Cancer Res 2014, 202:9-26.
14. Karlsson R, Aly M, Clements M, et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol 2014, 65:169-176.
15. Amoretti A, Laydner H, Bergfeld W Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis. J Am Acad Dermatol 2013, 68:937-943.
16. Rahman AA, Lophatananon A, Stewart-Brown S, et al. Hand pattern indicates prostate cancer risk. Br J Cancer 2011, 104:175-177. the UK Genetic Prostate Cancer Study Collaborators, the British Association of Urological Surgeons' Section of Oncologythe British Association of Urological Surgeons' Section of Oncology.
17. Zuccolo L, Harris R, Gunnell D, et al. Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol Biomarkers Prev 2008, 17:2325-2336.
18. Myles P, Evans S, Lophatananon A, et al. Diagnostic radiation procedures and risk of prostate cancer. Br J Cancer 2008, 98:1852-1856.
19. Nair-Shalliker V, Smith DP, Egger S, et al. Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: a case-control study. Int J Cancer 2012, 131:E726-E732.
20. Julin B, Wolk A, Johansson JE, Andersson SO, Andrén O, Akesson A Dietary cadmium exposure and prostate cancer incidence: a population-based prospective cohort study. Br J Cancer 2012, 107:895-900.
21. Sutcliffe S, Platz EA Inflammation and prostate cancer: a focus on infections. Curr Urol Rep 2008, 9:243-249.
22. Sutcliffe S, Neace C, Magnuson NS, Reeves R, Alderete JF Trichomonosis, a common curable STI, and prostate carcinogenesis-a proposed molecular mechanism. PLoS Pathog 2012, 8:e1002801.
23. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007, 7:256-269.
24. Huncharek M, Haddock KS, Reid R, Kupelnick B Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health 2010, 100:693-701.
25. Zu K, Giovannucci E Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control 2009, 20:1799-1810.
26. Discacciati A, Wolk A Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res 2014, 202:27-37.
27. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006, 15:1977-1983.
28. Loprinzi PD, Kohli M Effect of physical activity and sedentary behavior on serum prostate-specific antigen concentrations: results from the National Health and Nutrition Examination Survey (NHANES), 2003-2006. Mayo Clin Proc 2013, 88:11-21.
29. Liu Y, Hu F, Li D, et al. Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. Eur Urol 2011, 60:1029-1044.
30. Roddam AW, Allen NE, Appleby P, Key TJ Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008, 100:170-183. the Endogenous Hormones and Prostate Cancer Collaborative Group.
31. Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology 2008, 72:1240-1245.
32. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008, 149:461-471.
33. Ilic D, Neuberger MM, Djulbegovic M, Dahm P Screening for prostate cancer. Cochrane Database Syst Rev 2013, 1. CD004720.
34. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012, 104:125-132. the PLCO Project Team.
35. Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012, 366:981-990. the ERSPC Investigators.
36. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010, 7:303-311.
37. Wolters T, Roobol MJ, Steyerberg EW, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 2010, 126:2387-2393.
38. Haines IE, Gabor Miklos GL Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection. J Natl Cancer Inst 2013, 105:1534-1539.
39. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213. the Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group.
40. Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 2011, 185:1650-1655.
41. Vickers A, Cronin A, Roobol M, et al. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 2010, 28:2493-2498.
42. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999, 59:5975-5979.
43. Truong M, Yang B, Jarrard DF Toward the detection of prostate cancer in urine: a critical analysis. J Urol 2013, 189:422-429.
44. Leyten GH, Hessels D, Jannink SA, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014, 65:534-542.
45. Perdonà S, Bruzzese D, Ferro M, et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013, 73:227-235.
46. Vickers AJ, Ulmert D, Sjoberg DD, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 2013, 346:f2023.
47. Vickers AJ, Cronin AM, Björk T, et al. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 2010, 341:c4521.
48. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22:746-757. the European Society of Urogenital Radiology.
49. Lee DJ, Ahmed HU, Moore CM, Emberton M, Ehdaie B Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies. Curr Urol Rep 2014, 15:390.
50. Berney DM, Gopalan A, Kudahetti S, et al. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009, 100:888-893.
51. Reid AH, Attard G, Ambroisine L, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010, 102:678-684. the Transatlantic Prostate Group.
52. Lotan TL, Gurel B, Sutcliffe S, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011, 17:6563-6573.
53. FitzGerald LM, Agalliu I, Johnson K, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008, 8:230.
54. Toubaji A, Albadine R, Meeker AK, et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. Mod Pathol 2011, 24:1511-1520.
55. Ribeiro FR, Henrique R, Martins AT, Jerónimo C, Teixeira MR Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol 2007, 52:116-125.
56. Kudahetti S, Fisher G, Ambroisine L, et al. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int 2009, 104:20-24.
57. Ding Z, Wu CJ, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
58. Cuzick J, Swanson GP, Fisher G, et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011, 12:245-255. the Transatlantic Prostate Group.
59. Markert EK, Mizuno H, Vazquez A, Levine AJ Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci USA 2011, 108:21276-21281.
60. Pinsky PF, Crawford ED, Kramer BS, et al. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int 2007, 99:775-779.
61. Zackrisson B, Aus G, Lilja H, Lodding P, Pihl CG, Hugosson J Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening. Eur Urol 2003, 43:327-332.
62. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level
63. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014, 370:932-942.
64. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224.
65. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362:1192-1202. the REDUCE Study Group.
66. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) 2008, 1:174-181.
67. Robinson D, Garmo H, Bill-Axelson A, Mucci L, Holmberg L, Stattin P Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study. BMJ 2013, 346:f3406.
68. Schmitz-Dräger BJ, Schöffski O, Marberger M, Sahin S, Schmid HP Risk adapted chemoprevention for prostate cancer: an option?. Recent Results Cancer Res 2014, 202:79-91.
69. Thompson IM, Goodman PJ, Tangen CM, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med 2013, 369:603-610.
70. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998, 52:195-201. discussion 201-02.
71. Marberger M, Freedland SJ, Andriole GL, et al. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int 2012, 109:1162-1169.
72. Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012, 379:1103-1111.
73. Jiang L, Yang KH, Tian JH, et al. Efficacy of antioxidant vitamins and selenium supplement in prostate cancer prevention: a meta-analysis of randomized controlled trials. Nutr Cancer 2010, 62:719-727.
74. Druesne-Pecollo N, Latino-Martel P, Norat T, et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer 2010, 127:172-184.
75. Klein EA, Thompson IM, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011, 306:1549-1556.
76. Simoneau AR, Gerner EW, Nagle R, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2008, 17:292-299.
77. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012, 23:1403-1415.
78. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
79. Thorat MA, Cuzick J Role of aspirin in cancer prevention. Curr Oncol Rep 2013, 15:533-540.
80. Bansal D, Undela K, D'Cruz S, Schifano F Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One 2012, 7:e46691.
81. Bonovas S, Filioussi K, Sitaras NM Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008, 123:899-904.
82. Gilbert R, Martin RM, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 2011, 22:319-340.
83. Parnes HL, House MG, Tangrea JA Prostate cancer prevention: agent development strategies. Recent Results Cancer Res 2014, 202:121-131.
84. Ilic D, Forbes KM, Hassed C Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev 2011, 11. CD008007.
85. Etminan M, Takkouche B, Caamaño-Isorna F The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2004, 13:340-345.